A decade of esophageal cancer in Kazakhstan: what the national cancer registry reveals (2014–2023)

Background Esophageal cancer (EC) is a major yet understudied public health burden in Central Asia. Kazakhstan has one of the highest EC rates in the region, but national epidemiological trends and survival outcomes remain poorly reported. Epidemiological trends among younger adults are largely unexplored, despite growing concern about early-onset gastrointestinal cancers. This study assessed recent patterns in EC incidence, mortality, disease burden, and survival across Kazakhstan from 2014 to 2023. Methods We conducted a retrospective, population-based cohort study including all EC patients registered in the National Cancer Registry between Jan 1, 2014, and Dec 31, 2023. Demographic, clinical, and survival data were extracted from registry-linked records. Early-onset EC was defined as diagnosis before age 45. Age-standardized incidence, mortality, and prevalence rates per 100,000 were calculated using the WHO World Standard Population. DALYs were estimated following GBD 2023 methodology. Survival was assessed using Kaplan–Meier methods; predictors were analyzed with Cox regression. Results The cohort included 24,778 patients. The age-standardized incidence rate was 13.9 per 100,000 (95% CI 12.6–15.1). Mortality rose from 4.4 per 100,000 in 2014 to 10.6 per 100,000 in 2023, peaking at 12.3 per 100,000 in 2018. DALYs increased from 3,383 (95% UI 2,970–3,800) to 8,300 (95% UI 6,691–9,269) per 100,000, 95% attributable to YLL. In early-onset cases, DALYs per 100,000 tripled over ten years. Three-year survival declined from 62.9% (95% CI 59.2–66.6) at Stage I to 12.9% (95% CI 10.8–15.0) at Stage IV. Male sex (aHR 1.11), advanced stage (aHR 7.10), and alcohol disorders (aHR 1.15) were associated with poorer survival. Kyzylorda and Karaganda regions had the highest burden. Interpretation Despite stable incidence, EC mortality in Kazakhstan has tripled over the past decade, reflecting late-stage diagnosis, limited treatment access, and persistent modifiable risk factors such as alcohol and tobacco use. These findings highlight a critical public health gap and underscore the need for early detection programs and strengthened oncology infrastructure to reduce premature mortality in Kazakhstan and neighboring countries.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-03-12
DOI
https://doi.org/10.3389/fonc.2026.1762992
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A decade of esophageal cancer in Kazakhstan: what the national cancer registry reveals (2014–2023)

Abduzhappar Gaipov, Altay Kerimkulov, Ruslan Akhmedullin, Galiya Orazova et al.
Frontiers in Oncology
Esophageal Cancer Research and Treatment
article

A decade of esophageal cancer in Kazakhstan: what the national cancer registry reveals (2014–2023)

Abduzhappar Gaipov, Altay Kerimkulov, Ruslan Akhmedullin, Galiya Orazova, Altynay Beyembetova, Ayana Ablayeva, Diyora Abdukhakimova, Aigerim Biniyazova, Oxana Shatkovskaya, Zhandos Burkitbayev
article en

Abstract

Background Esophageal cancer (EC) is a major yet understudied public health burden in Central Asia. Kazakhstan has one of the highest EC rates in the region, but national epidemiological trends and survival outcomes remain poorly reported. Epidemiological trends among younger adults are largely unexplored, despite growing concern about early-onset gastrointestinal cancers. This study assessed recent patterns in EC incidence, mortality, disease burden, and survival across Kazakhstan from 2014 to 2023. Methods We conducted a retrospective, population-based cohort study including all EC patients registered in the National Cancer Registry between Jan 1, 2014, and Dec 31, 2023. Demographic, clinical, and survival data were extracted from registry-linked records. Early-onset EC was defined as diagnosis before age 45. Age-standardized incidence, mortality, and prevalence rates per 100,000 were calculated using the WHO World Standard Population. DALYs were estimated following GBD 2023 methodology. Survival was assessed using Kaplan–Meier methods; predictors were analyzed with Cox regression. Results The cohort included 24,778 patients. The age-standardized incidence rate was 13.9 per 100,000 (95% CI 12.6–15.1). Mortality rose from 4.4 per 100,000 in 2014 to 10.6 per 100,000 in 2023, peaking at 12.3 per 100,000 in 2018. DALYs increased from 3,383 (95% UI 2,970–3,800) to 8,300 (95% UI 6,691–9,269) per 100,000, 95% attributable to YLL. In early-onset cases, DALYs per 100,000 tripled over ten years. Three-year survival declined from 62.9% (95% CI 59.2–66.6) at Stage I to 12.9% (95% CI 10.8–15.0) at Stage IV. Male sex (aHR 1.11), advanced stage (aHR 7.10), and alcohol disorders (aHR 1.15) were associated with poorer survival. Kyzylorda and Karaganda regions had the highest burden. Interpretation Despite stable incidence, EC mortality in Kazakhstan has tripled over the past decade, reflecting late-stage diagnosis, limited treatment access, and persistent modifiable risk factors such as alcohol and tobacco use. These findings highlight a critical public health gap and underscore the need for early detection programs and strengthened oncology infrastructure to reduce premature mortality in Kazakhstan and neighboring countries.

Frontiers in OncologyVol. 16
Economic Development Board (SG), Astana Medical University (KZ), Nazarbayev University (KZ)
Good health and well-being
Openalex Percentile: Top 25%
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.